Drug Profile
Sintropium bromide
Alternative Names: VAL 480Latest Information Update: 23 Dec 2015
Price :
$50
*
At a glance
- Originator Valeas
- Class Analgesics
- Mechanism of Action Muscarinic receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Dystocia; Spasm
Most Recent Events
- 18 May 2001 No-Development-Reported for Spasm in Italy (Unknown route)
- 13 Feb 1997 Preregistration for Spasm in Italy (Unknown route)
- 25 Oct 1994 Phase-III clinical trials for Spasm in Italy (Unknown route)